KSKelly A. Shaw

Kelly A. Shaw

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kelly A. Shaw has a total of 156 co-authors. Here are the top co-authors by number of shared publications:

  • Walter Zahorodny

    Rutgers New Jersey Medical School, Newark

    7 shared publications
  • Josephine Shenouda

    Rutgers New Jersey Medical School, Newark

    6 shared publications
  • Matthew J. Maenner

    National Center on Birth Defects and Developmental Disabilities, US Centers for Disease Control and Prevention, Atlanta, Georgia

    6 shared publications
  • Anita Washington

    National Center on Birth Defects and Developmental Disabilities, US Centers for Disease Control and Prevention, Atlanta, Georgia

    5 shared publications
  • Maya Lopez

    University of Arkansas for Medical Sciences, Little Rock

    5 shared publications
  • Monica DiRienzo

    National Center on Birth Defects and Developmental Disabilities, US Centers for Disease Control and Prevention, Atlanta, Georgia

    5 shared publications

Latest Publications

  • Profound Autism Prevalence and Assessment Practices in a Population-Based Study

    by Kelly A. Shaw, Lauren A. Russell, Monica DiRienzo, Mary E. Patrick, Miguel Valencia-Prado, Deborah A. Bilder, Amy Esler, Karen Pierce, Sandra B. Vanegas, Anita Washington, et al.


  • Mortality Among Youth and Young Adults With Autism Spectrum Disorder, Intellectual Disability, or Cerebral Palsy

    by Kelly A. Shaw, Dedria McArthur, Deborah A. Bilder, Michelle M. Hughes, Charles E. Rose, Amanda V. Bakian, Maureen S. Durkin, Robert T. Fitzgerald, Ellen M. Howerton, Christine Ladd-Acosta, et al.

    Importance: Autism spectrum disorder (ASD), intellectual disability (ID), and cerebral palsy (CP) are lifelong neurodevelopmental conditions accompanied by varying impairments. US mortality data for these groups are limited. Objective: To compare mortality and causes of death among a multisite cohort identified at age 8 years with ASD, ID, or CP with the general population through youth or young adulthood. Design, Setting, and Participants: Nine US sites identified 32 787 individuals who met case definitions for ASD, ID, and/or CP at age 8 years during active population-based cross-sectional surveillance conducted biennially from 2000 through 2016 by the US Centers for Disease Control and Prevention’s Autism and Developmental Disabilities Monitoring (ADDM) Network. Individuals were linked to death certificates through 2021. Cases with multiple conditions (18.9%) were included in each case group. General population data from the National Vital Statistics System were matched to ADDM Network sites and years of participation. Analyses were completed in 2024. Exposure(s): ASD, ID, or CP. Main Outcomes and Measures: Death and International Classification of Diseases, 10th revision (ICD-10) International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) causes from death certificate linkage. Results: There were 145 deaths among 23 393 people with ASD, 285 deaths among 14 031 people with ID, and 123 deaths among 1612 people with CP. Increased mortality compared with the general population was seen for ASD (hazard ratio [HR], 1.35; 95% CI, 1.15-1.59), ID (HR, 4.35; 95% CI, 3.87-4.88), and CP (HR, 9.62; 95% CI, 8.06-11.48). Further stratified by sex and co-occurring ID, mortality for ASD was higher only for females with co-occurring ID (HR, 5.04; 95% CI,3.21-7.91) compared with females in the general population. The distribution of causes of death varied across groups. The most common underlying cause of death ICD-10 chapters were external causes of morbidity and mortality (V01-Y98) for the general population and ASD case group, and diseases of the nervous system (G00-G99) for CP and ID case groups. The only ICD-10 chapter hazard of death that was not elevated for ID and CP compared with the general population was external causes as underlying cause of death. Mortality from external causes was also not elevated as underlying or any cause of death for ASD. There were also notable subchapter mortality differences with important clinical and public health implications. Only 11% of those with ASD, 1% of those with ID, and 49% of those with CP had an ICD-10 code for the respective disability on their death certificate. Conclusions and Relevance: In this study, individuals with ASD, ID, or CP experienced higher mortality from a range of causes compared with the general population in youth and young adulthood. Mortality among these groups is difficult to ascertain using death certificates alone, since ICD-10 codes for these disabilities were rarely listed. These findings can inform public health and health care strategies to understand and prevent health disparities and excess mortality associated with developmental disabilities.


  • Open Access

    Prevalence of Autism Spectrum Disorder Severity Levels From the Fifth Edition of the Diagnostic and Statistical Manual (DSM-5) in the Autism and Developmental Disabilities Monitoring Network

    by Lauren A. Russell, Sarah C. Tinker, Kelly A. Shaw, Matthew J. Maenner, Monica Dirienzo, Anne V. Kirby, Ellen M. Howerton, Sandra B. Vanegas, Maya Lopez

    Purpose: The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) introduced severity level specifiers for autism spectrum disorder (ASD) with minimal description of the criteria for categorizing three levels of severity (1 to 3, with 3 being the most “severe”). The objective of the analysis was to assess the prevalence of ASD severity levels using population-based surveillance data. Methods: We analyzed severity level data on children with ASD ages 4- and 8-years-old in 2018 and 2020 in the multisite Autism and Developmental Disabilities Monitoring (ADDM) Network. Prevalence of any documented severity level and of each individual level were calculated overall and by demographic characteristics. Prevalence ratios adjusted for sex, race/ethnicity, age, intellectual disability, ADDM surveillance year, and site (aPRs) and 95% confidence intervals (CIs) were used for comparisons. Results: Less than half (40.4%) of children with documented ASD diagnoses had any severity level specified in their records, with wide variation by site (4.8%-73.2%). Severity levels were more common in records of children aged 4, in surveillance year 2020, and more often missing in non-Hispanic Black children and from records also missing information on intellectual disability (ID). Higher prevalence of more severe (level 3) ASD was observed among non-Hispanic Black children, children aged 4 years, children in 2020, and children with ID. Conclusion: Utilization of the DSM-5’s severity levels by community professionals varied widely, limiting their potential utility in identifying needed services and supports for children with ASD.


  • Navigating supplement use in para sport

    by Keely A. Shaw, Anneke Hertig-Godeschalk, Robyn F. Madden, Jill A. Parnell

    This chapter discusses supplement use in para athletes and provides insight into the potential benefits and risks. Para athletes have unique dietary requirements due to altered energy expenditure, nutrient needs, digestion, food choices, and exercise requirements. When nutritional needs cannot be met by a balanced diet or fortified foods alone, supplements can provide a useful strategy to support health or enhance performance. Dietary supplements for health, such as vitamins and minerals, can correct nutrient deficiencies, support growth and repair, and enhance immune function. Dietary supplements for exercise performance such as carbohydrates, protein, caffeine, and creatine provide convenient forms of energy and macronutrients and may enhance athletic performance. However, evidence to support the use of dietary supplements in para athletes is limited, with most guidelines extrapolated from the able-bodied population. Athletes and their support team should be aware of the risks and benefits of supplement use. Potential harms of inappropriate use include drug interactions, side effects, and contamination with banned substances leading to doping violations. An individualized approach with regular monitoring is needed and supplements should always be tested before competition. Future research on the efficacy of dietary supplements in different groups of para athletes is needed to improve recommendations.

  • Top Cited Papers
    Open Access

    Prevalence and Early Identification of Autism Spectrum Disorder Among Children Aged 4 and 8 Years — Autism and Developmental Disabilities Monitoring Network, 16 Sites, United States, 2022

    by Kelly A Shaw, Susan Williams, Mary E Patrick, Miguel Valencia-Prado, Maureen S Durkin, Ellen M Howerton, Christine M Ladd-Acosta, Elise T Pas, Amanda V Bakian, Paige Bartholomew, et al.

    This report describes autism spectrum disorder prevalence and early identifications patterns among children aged 4 and 8 years old.


  • Community testing practices for autism within the autism and developmental disabilities monitoring network

    by Ashley Robinson Williams, Esther Amoakohene, Matthew J. Maenner, Walter Zahorodny, Monica DiRienzo, Andrea Grzybowski, Jennifer Hall‐Lande, Elise T. Pas, Amanda V. Bakian, Maya Lopez, et al.

    Background: No data exist at the population level on what tests are used to aid in the diagnosis of autism spectrum disorder in community practice.Objectives: To describe autism spectrum disorder testing practices to inform autism spectrum disorder identification efforts.Methods: Data are from the Autism and Developmental Disabilities Monitoring Network, a multi‐site surveillance system reporting prevalence estimates and characteristics of 8‐year‐old children with autism spectrum disorder. Percentages of children with autism spectrum disorder who received any autism spectrum disorder test or a ‘gold standard’ test were calculated by site, sex, race, median household income, and intellectual ability status. Risk ratios were calculated to compare group differences.Results: Of 5058 8‐year‐old children with autism spectrum disorder across 11 sites, 3236 (64.0%) had a record of any autism spectrum disorder test and 2136 (42.2%) had a ‘gold standard’ ADOS or ADI‐R test. Overall, 115 children (2.3%) had both the ADOS and ADI‐R in their records. Differences persisted across race, median household income, and intellectual ability status. Asian/Pacific Islander children had the highest percent receiving any ASD test (71.8%; other groups range: 57.4–66.0%) and White children had the highest percent receiving ‘gold standard’ tests (46.4%; other groups range: 35.6–43.2%). Children in low‐income neighbourhoods had a lower percent of any test (62.5%) and ‘gold standard’ tests (39.4%) compared to medium (70.2% and 47.5%, respectively) and high (69.6% and 46.8%, respectively) income neighbourhoods. Children with intellectual disability had a lower percent of any ASD test (81.7%) and ‘gold standard’ tests (52.6%) compared to children without intellectual disability (84.0% and 57.6%, respectively).Conclusions: Autism spectrum disorder testing practices vary widely by site and differ by race and presence of co‐occurring intellectual disability, suggesting opportunities to standardise and/or improve autism spectrum disorder identification practices.


  • Top Cited Papers

    The Prevalence and Characteristics of Children With Profound Autism, 15 Sites, United States, 2000-2016

    by Michelle M. Hughes, Kelly A. Shaw, Monica DiRienzo, Maureen S. Durkin, Amy Esler, Jennifer Hall-Lande, Lisa Wiggins, Walter Zahorodny, Alison Singer, Matthew J. Maenner

    Objectives: Autism spectrum disorder (autism) is a heterogeneous condition that poses challenges in describing the needs of individuals with autism and making prognoses about future outcomes. We applied a newly proposed definition of profound autism to surveillance data to estimate the percentage of children with autism who have profound autism and describe their sociodemographic and clinical characteristics. Methods: We analyzed population-based surveillance data from the Autism and Developmental Disabilities Monitoring Network for 20 135 children aged 8 years with autism during 2000-2016. Children were classified as having profound autism if they were nonverbal, were minimally verbal, or had an intelligence quotient <50. Results: The percentage of 8-year-old children with profound autism among those with autism was 26.7%. Compared with children with non–profound autism, children with profound autism were more likely to be female, from racial and ethnic minority groups, of low socioeconomic status, born preterm or with low birth weight; have self-injurious behaviors; have seizure disorders; and have lower adaptive scores. In 2016, the prevalence of profound autism was 4.6 per 1000 8-year-olds. The prevalence ratio (PR) of profound autism was higher among non-Hispanic Asian/Native Hawaiian/Other Pacific Islander (PR = 1.55; 95 CI, 1.38-1.73), non-Hispanic Black (PR = 1.76; 95% CI, 1.67-1.86), and Hispanic (PR = 1.50; 95% CI, 0.88-1.26) children than among non-Hispanic White children. Conclusions: As the population of children with autism continues to change, describing and quantifying the population with profound autism is important for planning. Policies and programs could consider the needs of people with profound autism across the life span to ensure their needs are met.


  • Top Cited Papers

    Early Identification of Autism Spectrum Disorder Among Children Aged 4 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020

    by Kelly A Shaw, Deborah A Bilder, Dedria McArthur, Ashley Robinson Williams, Esther Amoakohene, Amanda V Bakian, Maureen S Durkin, Robert T Fitzgerald, Sarah M Furnier, Michelle M Hughes, et al.

    This report describes CDC findings from the Autism and Developmental Disabilities Monitoring Network for children aged 4 years in 2020.


  • Statewide county-level autism spectrum disorder prevalence estimates—seven U.S. states, 2018

    by Kelly A. Shaw, Susan Williams, Michelle M. Hughes, Zachary Warren, Amanda V. Bakian, Maureen S. Durkin, Amy Esler, Jennifer Hall-Lande, Angelica Salinas, Alison Vehorn, et al.